acetylleucine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 71 | 99-15-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
used for treating vestibular-related imbalance and vertigo
|
Drug dosage:
None
ADMET properties:
None
Approvals:
None
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Inappropriate antidiuretic hormone secretion | 65.96 | 52.52 | 16 | 386 | 15446 | 63473174 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Anticoagulation drug level above therapeutic | 75.63 | 65.72 | 14 | 377 | 2102 | 34954438 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hepatitis acute | 67.88 | 45.75 | 18 | 780 | 15524 | 79728066 |
| Anticoagulation drug level above therapeutic | 63.62 | 45.75 | 13 | 785 | 3607 | 79739983 |
| Haematoma | 61.11 | 45.75 | 22 | 776 | 52173 | 79691417 |
| Inappropriate antidiuretic hormone secretion | 50.13 | 45.75 | 16 | 782 | 26297 | 79717293 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N07CA04 | NERVOUS SYSTEM OTHER NERVOUS SYSTEM DRUGS ANTIVERTIGO PREPARATIONS Antivertigo preparations |
| CHEBI has role | CHEBI:25212 | metabolites |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.9 | acidic |
| pKa2 | 13.57 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| D07350 | KEGG_DRUG |
| 2375522 | RXNORM |
| C0256552 | UMLSCUI |
| CHEBI:166830 | CHEBI |
| CHEMBL1875805 | ChEMBL_ID |
| DB13226 | DRUGBANK_ID |
| CHEMBL56021 | ChEMBL_ID |
| 70912 | PUBCHEM_CID |
| 5209 | INN_ID |
| C088117 | MESH_SUPPLEMENTAL_RECORD_UI |
| K76S41V71X | UNII |
| DB16956 | DRUGBANK_ID |
| 735136009 | SNOMEDCT_US |
| 005881 | NDDF |
Pharmaceutical products:
None